Search Results
Nov 10, 2025, 16:05 ET Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
ongoing Phase 3 CYPRESS study. TRELEGY GSK reported third quarter 2025 global net sales of approximately $1.0 billion (up 24% vs. the third quarter of 2024) and year-to-date net sales of approximately
More news about: Theravance Biopharma, Inc.
Nov 10, 2025, 10:50 ET ERS Genomics and Dyadic Applied BioSolutions Sign CRISPR/Cas9 License Agreement
synthetic biology, including production of enzymes, food ingredients, and bio-based chemicals. Current ERS licensees include GSK, Merck, Bayer, Thermo Fisher Scientific, Corteva, Danaher, PerkinElmer, Charles River Laboratories, and Cargill. For more information, visit
More news about: ERS Genomics
Nov 06, 2025, 17:31 ET Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight
more effective therapeutic strategies to enhance clinical outcomes. Major companies such as Merck, Karyopharm Therapeutics, Faeth Therapeutics, and GSK are actively pursuing the development of novel candidates across various stages of clinical research. To know more about endometrial
More news about: DelveInsight Business Research, LLP
Nov 05, 2025, 09:12 ET EASTERSEALS NATIONAL BOARD OF DIRECTORS ELECTS NEW BOARD MEMBERS AND OFFICERS
unanimously reelected Board Chair for an additional two-year term. Other officers elected include Wanda Hill, RPh, JD, VP of U.S. Regulatory Affairs, GSK, as First Vice-Chair; Greg Sexton, Chief Operating Officer, Century 21 Real Estate LLC, as Second Vice-Chair; Dr. Kaveh Safavi, MD, JD, Senior Managing
More news about: Easterseals
Nov 04, 2025, 17:31 ET Cholestatic Pruritus Market is Predicted to Exhibit Remarkable Growth at a CAGR of 23.4% in the US During the Forecast Period (2025-2034) | DelveInsight
pruritus market in the coming years. The promising cholestatic pruritus therapies in clinical trials include Linerixibat (GSK2330672), Volixibat, TH104 (nalmefene), and others. Estimates suggest that Linerixibat will generate approximately
More news about: DelveInsight Business Research, LLP
Nov 04, 2025, 06:20 ET Next-Generation Multiple Myeloma Therapies Market to Reach USD 37.07 Billion by 2033, Driven by Accelerated Immunotherapy Approvals and Precision Medicine Advances - DataM Intelligence
Abecma in combination with bispecific antibodies to achieve dual-target BCMA/GPRC5D response. GSK plc reported new data for Blenrep (belantamab mafodotin) with a median duration of response of 12.9 months, reinforcing ADC efficacy.
More news about: DataM Intelligence 4 Market Research LLP
Nov 04, 2025, 06:00 ET IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
the end of 2025. IDE275 (GSK959), a potential first-in-class small molecule inhibitor of Werner Helicase, is being developed in collaboration with GlaxoSmithKline (GSK). A Phase 1 dose escalation in patients with MSI-High solid tumors is ongoing.
More news about: IDEAYA Biosciences, Inc.
Nov 04, 2025, 06:00 ET Softgels Dietary Supplements Market to Surpass USD 358.6 Billion by 2032, Driven by Rising Preventive Health Awareness and E-Commerce Expansion | DataM Intelligence
Abbott | Herbalife International of America Inc. | NOW Foods | Glanbia plc | Amway India Enterprises Pvt Ltd | dsm-firmenich | The Nature's Bounty | GSK plc | Rouzel Pharma Pvt Ltd Bayer AG holds 6.8% global market
More news about: DataM Intelligence 4 Market Research LLP
Nov 04, 2025, 05:00 ET BizClik Launches Dual Middle East Summits for Sustainability, Procurement, and Supply Chain Leaders 2026
Past attendees of Procurement & Supply Chain LIVE programmes include executives from Emirates, Heineken, MTN, ABB, GSK, Nestlé, Baker Hughes, Nando's, and The Coca-Cola Company. Join
More news about: BizClik Media
Oct 30, 2025, 10:30 ET Cystic Fibrosis (CF) Therapeutics Market to Reach $17.1 billion by 2027 in the short term and $32.3 billion by 2034 Globally, at 9.6% CAGR: Allied Market Research
Lupin Chiesi Farmaceutici S.p.A. Digestive Care, Inc., GSK plc. Between 2021 and 2025, product approvals and clinical trials have emerged as the most prominent activities
More news about: Allied Market Research
Oct 30, 2025, 08:52 ET Global Location Strategies Report: $350 Billion U.S. Pharmaceutical Manufacturing Investment Boom Challenged by Labor Shortages, Tariffs and Policy Shifts
The policy has already triggered new long-term investments from AstraZeneca ($50B), Johnson & Johnson ($55B), GSK ($30B), and Eli Lilly ($11.5B). Exemptions exist for companies making substantial U.S. manufacturing investments.
More news about: Global Location Strategies
Oct 30, 2025, 08:00 ET Google Cloud to Host Second-Annual Cancer AI Symposium in New York City
organizations like Stand Up To Cancer, Every Cure, Google DeepMind, and Google for Health, will demonstrate how AI is making cancer care more human and GSK will share strategies on navigating hurdles to turn vision into concrete delivery and action. At the symposium,
More news about: Google Cloud
Oct 27, 2025, 14:27 ET Syngene International announces plans to add bioconjugation suite for end-to-end Antibody-Drug Conjugates Development
with around 400 global customers across industry segments, including biotech companies pursuing leading-edge science and multinationals such as BMS, GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com. For the
More news about: Syngene International
Oct 27, 2025, 12:00 ET Sword Joins ISA Global Cybersecurity Alliance and ISASecure to Advance Adoption of ISA/IEC 62443 Standards
internationally recognized benchmarks for OT security. ISASecure's global ecosystem includes leaders such as Chevron, ExxonMobil, GSK, Saudi Aramco, Honeywell, Johnson Controls, Schneider Electric, Trane Technologies and Yokogawa, among others. For more information,
More news about: The International Society of Automation
Oct 23, 2025, 17:31 ET Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight
nivolumab + ipilimumab combination, has expanded in dMMR/MSI-H metastatic colorectal cancer, reinforcing PD-1 leadership. Approvals of dostarlimab (GSK) and durvalumab (AstraZeneca) in dMMR endometrial cancer are moving checkpoint therapy earlier in treatment lines and into combination regimens,
More news about: DelveInsight Business Research, LLP
Oct 21, 2025, 17:31 ET Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | DelveInsight
candidates like SAR447537 (Sanofi), Alvelestat (Mereo BioPharma), BEAM-302 (Beam Therapeutics), itepekimab (Regeneron Pharmaceuticals/Sanofi), depemokimab (GSK), and others are demonstrating a strong commitment to tackling the unmet medical need, with ongoing initiatives aimed at introducing innovative treatment
More news about: DelveInsight Business Research, LLP
Oct 19, 2025, 19:00 ET Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
and bacterial infectious disease targets. He has previously held leadership positions at esteemed infectious disease R&D organizations including GSK, Pfizer and Sanofi, where he was the Head of Global Research for Sanofi Pasteur, responsible for leading vaccine research and early development activities
More news about: Clover Biopharma
Oct 17, 2025, 15:36 ET At 2025 STAT Summit, Guests including Joe Kennedy III, AMA President, Former NIH Leaders, Explore CRISPR, Pharma, Public Health, and More
STAT Emma Walmsley, John Maraganore, and Christopher Viehbacher GSK CEO Emma Walmsley, former Alnylam CEO John Maraganore, and Biogen CEO Christopher Viehbacher discussed everything from vaccines and public trust to the
More news about: STAT
Oct 17, 2025, 10:16 ET Syngene International invests in dedicated peptide laboratory and advanced automation
with around 400 global customers across industry segments, including biotech companies pursuing leading-edge science and multinationals such as BMS, GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com. For the
More news about: Syngene International
Oct 15, 2025, 17:31 ET Gastrointestinal Neuroendocrine Tumors Market Set to Surge by 2034 Amidst Advancements in Treatment Options | DelveInsight
key GEJ-NET companies, including Novartis, Ipsen, Bristol-Myers Squibb, Merck, Pfizer, Amgen, Teva Pharmaceutical, Eli Lilly and Company, HUTCHMED, GSK, among others. About DelveInsight DelveInsight is a leading
More news about: DelveInsight Business Research, LLP
Oct 15, 2025, 08:00 ET Ouro Medicines Announces Expansion of Clinical Development for OM336 in Sjögren's Disease and Idiopathic Inflammatory Myopathy
remissions without ongoing immunosuppression. Based in San Francisco and launched in 2025, Ouro was founded by Monograph Capital in partnership with GSK. Ouro is also backed by leading investors TPG, NEA and Norwest. For more information visit
More news about: Ouro Medicines
Oct 14, 2025, 15:31 ET Health and Wellness Food Market to Reach USD 2,177.10 billion by 2032, Growing At An 9.80% CAGR - Credence Research
Kellogg Co. (U.S.) Nestlé (Switzerland) Yakult Honsha Co., Ltd. (Japan) GSK plc. (U.K.) Recent Industry Developments
More news about: Credence Research Inc.
Oct 14, 2025, 06:18 ET Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults
RSV re-vaccination trial demonstrates ≥60% higher trend in RSV neutralizing antibodies for Clover's RSV vaccine compared head-to-head versus AREXVY (GSK) in older adults previously receiving an initial dose of AREXVY -- -- Potential first-in-class RSV+hMPV±PIV3
More news about: Clover Biopharma
Oct 13, 2025, 00:38 ET GC Biopharma Secures CMO Rights for Shingles Vaccine from Curevo Vaccine
vaccine business through strategic collaborations and differentiated technologies." [1] Source: GSK Q4 2024 Earnings Announcement About GC Biopharma GC Biopharma
More news about: GC Biopharma
Oct 09, 2025, 10:01 ET Cardiovascular Drugs Market to 2030: APAC Leads Growth and Telehealth Helps Online Pharmacies Expand, Says Mordor Intelligence
AbbVie Amgen Daiichi Sankyo Novo Nordisk GSK Takeda Abbott Laboratories Roche Servier
More news about: Mordor Intelligence Private Limited